KRAS and lung cancer: As illustrated in Fig. 2d, we tested the combo treatment on the KRAS-driven lung cancer (LSL KrasG12D) model, which leads to adenocarcinomas 4 months after instillation of adenoviruses expressing the Cre recombinase18.